整合代谢组学与临床特征提高多囊卵巢综合征诊断准确性与疗效:随机对照试验研究方案
本方案为前瞻性、多中心、分析者盲法随机对照试验,计划纳入276人(60名健康对照、216例PCOS患者),将216例患者按1:1随机分入临床指标诊断组与代谢组学指标诊断组,各接受不同6个月治疗,主要结局为PCOS治疗效果,旨在比较两种诊断方式的准确性与疗效。
要点
- 比较代谢组学指标与临床特征诊断PCOS表型的准确性与疗效。
- 216例PCOS患者按1:1随机分两组,各接受不同6个月治疗。
- 主要结局为实验组的PCOS治疗效果。
核心结论
- 该试验旨在确定代谢组学指标诊断PCOS表型是否比临床特征更准确有效。
- 结果可为PCOS不同亚组的精准诊断及个体化治疗研究奠定基础。
研究设计与样本
- 前瞻性、多中心、分析者盲法随机对照试验。
- 计划招募276名参与者,包括60名健康人和216例PCOS患者。
- 216例PCOS患者按1:1随机分配至两个实验组,各接受不同6个月治疗。
关键数值与推荐
- 分组为:无PCOS的健康对照组、基于临床指标诊断PCOS的实验组1、基于代谢组学指标诊断PCOS的实验组2。
- 实验组主要结局为PCOS治疗效果。
- 试验注册于中国临床试验注册中心,ID:ChiCTR-INR-1800016346,注册日期2018年5月26日。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycystic ovary syndrome (PCOS) is a complex endocrine syndrome with poorly understood mechanisms. To provide patients with PCOS with individualized therapy, it is critical to precisely diagnose the phenotypes of the disease. However, the criteria for diagnosing the different phenotypes are mostly based on symptoms, physical examination and laboratory results. This study aims to compare the accuracy and efficacy of diagnosing PCOS by integrating metabolomic markers with common clinical characteristics. METHODS: This is a prospective, multicenter, analyst-blinded, randomized controlled trial. Participants will be grouped into (1) people without PCOS (healthy control group), (2) patients diagnosed with PCOS based on clinical indices (experimental group 1), and (3) patients diagnosed with PCOS based on metabolomic indices (experimental group 2). A total of 276 participants, including 60 healthy people and 216 patients with PCOS, will be recruited. The 216 patients with PCOS will be randomly assigned to the two experimental groups in a 1:1 ratio, and each group will receive a different 6-month treatment. The primary outcome for the experimental groups will be the effect of PCOS treatment. DISCUSSION: The results of this trial should help to determine whether using metabolomic indices is more accurate and effective than using clinical characteristics in diagnosing the phenotypes of PCOS. The results could provide a solid foundation for the accurate diagnosis of different PCOS subgroups and for future research on individualized PCOS therapy. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ID: ChiCTR-INR-1800016346. Registered 26 May 2018.
引用
- Ni CM, Huang WL, Jiang YM, et al. Improving the accuracy and efficacy of diagnosing polycystic ovary syndrome by integrating metabolomics with clinical characteristics: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32046752. doi:10.1186/s13063-020-4060-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。